Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms

[1]  N. Magné,et al.  Current trials of cytotoxic and targeted agents in breast cancer: the caveat of radiotherapy. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  K. Sandelin,et al.  Outcome of treatment for ipsilateral breast tumor recurrence in early-stage breast cancer , 1998, Breast Cancer Research and Treatment.

[3]  J. Bryant,et al.  Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Osborne,et al.  Steroid hormone receptors in breast cancer management , 2004, Breast Cancer Research and Treatment.

[5]  J. Manola,et al.  Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Reimer,et al.  Concurrent Radiotherapy and Taxane Chemotherapy in Patients with Locoregional Recurrence of Breast Cancer , 2006, Strahlentherapie und Onkologie.

[7]  M. Deutsch.  Repeat high-dose external beam irradiation for in-breast tumor recurrence after previous lumpectomy and whole breast irradiation. , 2002, International journal of radiation oncology, biology, physics.

[8]  M. Gilcrease,et al.  Ki-67 as Prognostic Marker in Early Breast Cancer: A Meta-analysis of Published Studies Involving 12 155 Patients , 2008 .

[9]  D. Banerjee,et al.  Mastectomy follow-up by biennial mammograms: is it worthwhile? , 2000, Breast.

[10]  D. Page,et al.  Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. , 1992, Human pathology.

[11]  C. Shapiro,et al.  Treatment of metastatic breast cancer: present and future prospects. , 1995, Seminars in oncology.

[12]  R. Calderon-Margalit,et al.  Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: A critical review of the literature , 2004, International journal of cancer.

[13]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[14]  T. Nishikawa,et al.  The combination of angiogenesis and blood vessel invasion as a prognostic indicator in primary breast cancer , 2003, British Journal of Cancer.

[15]  Umberto Veronesi,et al.  A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. , 2003, The New England journal of medicine.

[16]  M. Fiatarone Singh,et al.  Progressive resistance training in breast cancer: a systematic review of clinical trials , 2008, Breast Cancer Research and Treatment.

[17]  P Selby,et al.  Benefits from specialised cancer care , 1996, The Lancet.

[18]  D. Franceschi,et al.  Metastasectomy as a cytoreductive strategy for treatment of isolated pulmonary and hepatic metastases from breast cancer. , 1999, Surgical oncology.

[19]  N. Magné,et al.  Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment. , 2011, Cancer treatment reviews.

[20]  P. V. van Diest,et al.  Micrometastases or isolated tumor cells and the outcome of breast cancer. , 2009, The New England journal of medicine.

[21]  W. Kun,et al.  Absolute Risk Reductions for Local Recurrence after Postoperative Radiotherapy after Sector Resection for Ductal Carcinoma in Situ of the Breast , 2011 .

[22]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  O. Olopade,et al.  Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. , 2006, The Lancet. Oncology.

[24]  Mark Levine,et al.  Radiation therapy and tamoxifen: concurrent or sequential? That is the question. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Peto,et al.  Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. , 2010, Journal of the National Cancer Institute. Monographs.

[26]  J. Bergh,et al.  ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  L Biganzoli,et al.  Quality indicators in breast cancer care. , 2010, European journal of cancer.

[28]  J. Benítez,et al.  Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations , 2006, Oncogene.

[29]  A. Lipton,et al.  Metastatic breast cancer: overview of treatment. , 2003, Clinical orthopaedics and related research.

[30]  J. Kanis,et al.  Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  H. Dickinson,et al.  Surgical resection and whole brain radiation therapy versus whole brain radiation therapy alone for single brain metastases. , 2005, The Cochrane database of systematic reviews.

[32]  R. Souchon,et al.  DEGRO Practical Guidelines for Radiotherapy of Breast Cancer I , 2007, Strahlentherapie und Onkologie.

[33]  S. Haga,et al.  Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer , 2003, Breast cancer.

[34]  M. Indelli,et al.  Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. , 1994, JAMA.

[35]  James Dignam,et al.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial , 1999, The Lancet.

[36]  Z. Gokaslan,et al.  Thoracolumbar spine: Surgical treatment of metastatic disease , 2003 .

[37]  E. van Limbergen,et al.  Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[38]  M. Barton,et al.  An evidence-based estimation of local control and survival benefit of radiotherapy for breast cancer. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  E. Berthelet,et al.  Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[40]  M. Stockler,et al.  Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. , 2000, Cancer treatment reviews.

[41]  F. B. Sørensen,et al.  Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Christiaens,et al.  Different physical treatment modalities for lymphoedema developing after axillary lymph node dissection for breast cancer: a review. , 2010, European journal of obstetrics, gynecology, and reproductive biology.

[43]  P. Goss,et al.  Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. , 1996, Journal of Clinical Oncology.

[44]  L. Demange,et al.  A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. , 2006, International journal of radiation oncology, biology, physics.

[45]  S. Groshen,et al.  Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  A. Pedotti,et al.  Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ , 2003, The Lancet.

[47]  S. Márquez-Calderón,et al.  Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: A systematic review , 2007, International journal of cancer.

[48]  P. Fasching,et al.  Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials , 2010, Breast Cancer Research and Treatment.

[49]  Guidelines for the management of symptomatic breast disease. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[50]  M. Levine,et al.  Clinical practice guidelines for the care and treatment of breast cancer: 11. Lymphedema. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[51]  R. Epstein,et al.  Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study , 1997, BMJ.

[52]  C. Farquhar,et al.  High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. , 2005, The Cochrane database of systematic reviews.

[53]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[54]  D. Aguiar-Bujanda,et al.  False Elevation of Serum CA 15‐3 Levels in Patients Under Follow‐Up for Breast Cancer , 2004, The breast journal.

[55]  D. Page,et al.  Routinely available indicators of prognosis in breast cancer , 2004, Breast Cancer Research and Treatment.

[56]  M. Trudeau,et al.  The Role of Trastuzumab (Herceptin ) in the Treatment of Women with HER2/neu-overexpressing Metastatic Breast Cancer , 2005 .

[57]  Eduardo Bruera,et al.  Treatment decisions for breast carcinoma , 2002, Cancer.

[58]  C. Gross,et al.  Effectiveness of radiation therapy in older women with ductal carcinoma in situ. , 2006, Journal of the National Cancer Institute.

[59]  C. Bressac,et al.  Is breast conservation after local recurrence feasible? , 1991, European journal of cancer.

[60]  Diethelm Wallwiener,et al.  A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance , 2005, Cancer.

[61]  D. Hayes.  Clinical practice. Follow-up of patients with early breast cancer. , 2007, The New England journal of medicine.

[62]  A. Schwer,et al.  Impact of postmastectomy radiotherapy in T3N0 invasive carcinoma of the breast , 2008, Cancer.

[63]  A. Howell,et al.  Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. , 2001, Cancer journal.

[64]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[65]  V Torri,et al.  Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  D. Forman,et al.  Automated collection of quality-of-life data: a comparison of paper and computer touch-screen questionnaires. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  E. Winer,et al.  American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  M. Ellis,et al.  Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women , 2003, Cancer.

[69]  P. Hoskin,et al.  A role for radiotherapy in neuropathic bone pain: preliminary response rates from a prospective trial (Trans-tasman radiation oncology group, TROG 96.05) , 2000, International journal of radiation oncology, biology, physics.

[70]  F. B. Sørensen,et al.  Impact of BCL2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer. A subgroup analysis of DBCG82 b&c , 2008, Acta oncologica.

[71]  R. Peto,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.

[72]  G. Hortobagyi,et al.  Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  E. Perez,et al.  Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  S. Ciatto,et al.  Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. , 1994, JAMA.

[75]  B. Cady,et al.  New therapeutic possibilities in primary invasive breast cancer. , 1993, Annals of surgery.

[76]  J. Forbes,et al.  Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11– , 2001 .

[77]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  D. Voskuil,et al.  Maintenance of physical activity and body weight in relation to subsequent quality of life in postmenopausal breast cancer patients. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  G. Sgourakis,et al.  Comparison of Skin-Sparing Mastectomy Versus Non–Skin-Sparing Mastectomy for Breast Cancer: A Meta-Analysis of Observational Studies , 2010, Annals of surgery.

[80]  A. Goldhirsch,et al.  Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomy. , 2010, Cancer treatment reviews.

[81]  G. Hortobagyi,et al.  Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  N. Piller,et al.  A systematic review of common conservative therapies for arm lymphoedema secondary to breast cancer treatment. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[83]  R. Newcombe,et al.  Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer , 2006, Breast Cancer Research and Treatment.

[84]  G. Sledge,et al.  Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  R. Müller,et al.  The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial. , 2008, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[86]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[87]  Karla Kerlikowske,et al.  Mammography Surveillance Following Breast Cancer , 2003, Breast Cancer Research and Treatment.

[88]  S. Barni,et al.  Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better , 2012, Medical Oncology.

[89]  W. Woodward,et al.  The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer. , 2008, European journal of cancer.

[90]  S. Martino,et al.  Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. , 2000, The New England journal of medicine.

[91]  Y. Fujiwara,et al.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  A. Edwards,et al.  Psychological interventions for women with metastatic breast cancer. , 2008, The Cochrane database of systematic reviews.

[93]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[94]  S. Tyldesley,et al.  Ten-year locoregional recurrence risks in women with nodal micrometastatic breast cancer staged with axillary dissection. , 2011, International journal of radiation oncology, biology, physics.

[95]  J Kievit,et al.  The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[96]  Mike Clarke,et al.  EFFECTS OF RADIOTHERAPY AND SURGERY IN EARLY BREAST-CANCER - AN OVERVIEW OF THE RANDOMIZED TRIALS , 1995 .

[97]  N. Bundred,et al.  Prognostic and predictive factors in breast cancer. , 2001, Cancer treatment reviews.

[98]  B. Haffty,et al.  Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  P. V. van Diest,et al.  Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: A long term follow‐up analysis , 2004, Journal of surgical oncology.

[100]  M. Héry,et al.  Radiotherapy for invasive breast cancer: guidelines for clinical practice from the French expert review board of Nice/Saint-Paul de Vence. , 2011, Critical reviews in oncology/hematology.

[101]  I. Ellis,et al.  Predictors of response to second-line endocrine therapy for breast cancer , 1997, Breast Cancer Research and Treatment.

[102]  L. Norton,et al.  Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  I. Barillot,et al.  Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[104]  T. Nemoto,et al.  THE MANAGEMENT OF ADVANCED BREAST CANCER , 1970, The Medical journal of Australia.

[105]  K. Linde,et al.  Mistletoe therapy in oncology. , 2008, The Cochrane database of systematic reviews.

[106]  Andreas Makris,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  J. Yahalom,et al.  [Treatment of metastatic breast cancer]. , 1986, Harefuah.

[108]  J. Cuzick,et al.  Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial , 2010, The Lancet. Oncology.

[109]  Richard L Schilsky,et al.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  F. Cavalli,et al.  First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  C. Hudis,et al.  Follow-up care of breast cancer survivors. , 2003, Critical reviews in oncology/hematology.

[112]  M. Namer,et al.  Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[113]  S J Schnitt,et al.  Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  W. Woodward,et al.  Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. , 2007, International journal of radiation oncology, biology, physics.

[115]  Xueri Li,et al.  Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients:The FNCLCC PACS 01 Trial , 2009 .

[116]  C. de Wolf,et al.  European guidelines for quality assurance in the surgical management of mammographically detected lesions. , 1998, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[117]  K. Engelmann,et al.  Liver metastases: interventional therapeutic techniques and results, state of the art , 1999, European Radiology.

[118]  T. Whelan,et al.  Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial. Investigators of the Ontario Clinical Oncology Group. , 1994, International journal of radiation oncology, biology, physics.

[119]  Umberto Veronesi,et al.  Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. , 2002, The New England journal of medicine.

[120]  M. Koizumi,et al.  Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[121]  P. Maguire,et al.  The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses , 1999, British Journal of Cancer.

[122]  N. Brünner,et al.  Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. , 2002, Journal of the National Cancer Institute.

[123]  S. Teutsch,et al.  Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? , 2009, Genetics in Medicine.

[124]  Y. Takatsuka.  [Clinical practice guideline for breast cancer]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.

[125]  Radiotherapy for bone metastases. , 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

[126]  J. Peterse,et al.  Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  S. Martino,et al.  Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[129]  C. Kelly,et al.  Treatment of metastatic disease of the tibia. , 2003, Clinical orthopaedics and related research.

[130]  M. Morrow.  Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group , 2007 .

[131]  Andreas Schneeweiss,et al.  Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  A. Luini,et al.  Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[133]  B J McNeil,et al.  Computed tomography, ultrasound, and scintigraphy of the liver in patients with colon or breast carcinoma: a prospective comparison. , 1983, Radiology.

[134]  L. Solin,et al.  Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  A. Howell,et al.  Risk reducing mastectomy: outcomes in 10 European centres , 2008, Journal of Medical Genetics.

[136]  S. Ciatto,et al.  Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. , 1999, JAMA.

[137]  M Baum,et al.  Polychemotherapy for early breast cancer: An overview of the randomised trials , 1998 .

[138]  F. Cramp,et al.  Exercise for the management of cancer-related fatigue in adults. , 2008, The Cochrane database of systematic reviews.

[139]  I. Ellis,et al.  Value of Contralateral Surveillance Mammography for Primary Breast Cancer Follow-up , 2000, World Journal of Surgery.

[140]  B Fisher,et al.  Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. , 1997, Journal of the National Cancer Institute.

[141]  M. Ozsahin,et al.  Identifying patients at risk for late radiation-induced toxicity. , 2012, Critical reviews in oncology/hematology.

[142]  Choll W. Kim,et al.  Metastatic disease of the spine: evaluation and treatment. , 2003, Clinical orthopaedics and related research.

[143]  D. McCready,et al.  Management of Ductal Carcinoma in Situ of the Breast: A Clinical Practice Guideline , 2006 .

[144]  Management of breast cancer in women with BRCA gene mutation , 2007, BMJ : British Medical Journal.

[145]  Andrew Hanby,et al.  Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial , 2010, The Lancet.

[146]  B. Newman,et al.  Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up , 2005, Breast Cancer Research and Treatment.

[147]  G. Storme,et al.  Survival Benefit with Radiation Therapy in Node-Positive Breast Carcinoma Patients , 2009, Strahlentherapie und Onkologie.

[148]  C. Carter,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989, Cancer.

[149]  D Machin,et al.  Relationship between thermal dose and outcome in thermoradiotherapy treatments for superficial recurrences of breast cancer: data from a phase III trial Sherar, , 2004 .

[150]  D. Wickerham,et al.  Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[151]  N. Wolmark,et al.  Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. , 2001, Seminars in oncology.

[152]  T. Julian,et al.  Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. , 2010, The Lancet. Oncology.

[153]  N. Wald,et al.  UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening , 1995, BMJ.

[154]  M. Bollet,et al.  [Monocentric evaluation of the skin and cardiac toxicities of the concomitant administration of trastuzumab and radiotherapy]. , 2009, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[155]  A. Recht.  Integration of systemic therapy and radiation therapy for patients with early-stage breast cancer treated with conservative surgery. , 2003, Clinical breast cancer.

[156]  F. Facciolo,et al.  Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[157]  R. Schulz-Wendtland,et al.  [BI-RADS-analogue DEGUM criteria for findings in breast ultrasound--consensus of the DEGUM Committee on Breast Ultrasound]. , 2006, Ultraschall in der Medizin.

[158]  N. Rowell.  Are mastectomy resection margins of clinical relevance? A systematic review. , 2010, Breast.

[159]  Anna L. Brown,et al.  Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[160]  T. Helbich,et al.  [Cost-effectiveness of percutaneous core needle breast biopsy (CNBB) versus open surgical biopsy (OSB) of nonpalpable breast lesions: metaanalysis and cost evaluation for German-speaking countries]. , 2008, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[161]  D. Ghersi,et al.  Taxanes for adjuvant treatment of early breast cancer. , 2007, The Cochrane database of systematic reviews.

[162]  J. Gazet,et al.  The importance of the resection margin in conservative surgery for breast cancer. , 1996, European Journal of Surgical Oncology.

[163]  J. Smallwood,et al.  Diagnosis and treatment of early breast cancer, including locally advanced disease—summary of NICE guidance , 2009, BMJ : British Medical Journal.

[164]  H. Hauner,et al.  The effect of overweight and nutrition on prognosis in breast cancer. , 2011, Deutsches Arzteblatt international.

[165]  Les Irwig,et al.  Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[166]  S. Cawthorn,et al.  Reporting clinical outcomes of breast reconstruction: a systematic review. , 2011, Journal of the National Cancer Institute.

[167]  C. Vogel,et al.  Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[168]  M. Kosir,et al.  Improving surgical outcomes: standardizing the reporting of incidence and severity of acute lymphedema after sentinel lymph node biopsy and axillary lymph node dissection. , 2006, American journal of surgery.

[169]  R. Gelber,et al.  Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. , 2008, Journal of the National Cancer Institute.

[170]  C. Grau,et al.  Loco-regional recurrence after mastectomy in high-risk breast cancer--risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[171]  H. Mouridsen,et al.  Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG , 1999, European journal of cancer.

[172]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[173]  A. Stratiev,et al.  [Classification of malignant tumours of salivary glands by TNM system]. , 1989, Stomatologiia. Stomatology.

[174]  K. Horst,et al.  Fractionation for whole breast irradiation: An American Society for Radiation Oncology (ASTRO) evidence-based guideline , 2012 .

[175]  A. Lluch,et al.  Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. , 2007, Cancer treatment reviews.

[176]  D A Berry,et al.  Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. , 1998, Journal of the National Cancer Institute.

[177]  M. J. van de Vijver,et al.  Postmastectomy radiotherapy: will the selective use of postmastectomy radiotherapy study end the debate? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[178]  R. Kreienberg,et al.  Stufe-3-Leitlinie – Brustkrebs-Früherkennung in Deutschland , 2003, Der Onkologe.

[179]  D. Weaver,et al.  Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma , 2000, Cancer.

[180]  Jane M. Young,et al.  Health professional and consumer views on involving breast cancer patients in the multidisciplinary discussion of their disease and treatment plan , 2007, Cancer.

[181]  G. Hortobagyi,et al.  Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. , 2005, International journal of radiation oncology, biology, physics.

[182]  L. Holmberg,et al.  SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening , 2006, Acta oncologica.

[183]  M. Galantino,et al.  Exercise Interventions for Upper Limb Dysfunction Due to Breast Cancer Treatment , 2013, Physical Therapy.

[184]  L. Livi,et al.  Benefit of radiation boost after whole-breast radiotherapy. , 2009, International journal of radiation oncology, biology, physics.

[185]  M. Golshan,et al.  Sentinel Lymph Node Biopsy Lowers the Rate of Lymphedema When Compared with Standard Axillary Lymph Node Dissection , 2003, The American surgeon.

[186]  P. Bult,et al.  Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. , 2010, Journal of the National Cancer Institute.

[187]  A. Kuten,et al.  Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider. , 2010, The oncologist.

[188]  M. Bani,et al.  Lymphedema in breast cancer survivors: assessment and information provision in a specialized breast unit. , 2007, Patient education and counseling.

[189]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[190]  C. Boni,et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[191]  Eva Grunfeld,et al.  Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update) , 2005, Canadian Medical Association Journal.

[192]  L D Lunsford,et al.  Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. , 1999, International journal of radiation oncology, biology, physics.

[193]  Monica Morrow,et al.  Locoregional treatment of primary breast cancer , 2010, Cancer.

[194]  C. Meisner,et al.  Symptom-Oriented Follow-Up of Early Breast Cancer Is not Inferior to Conventional Control. Results of a Prospective Multicentre Study , 2007, Oncology Research and Treatment.

[195]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[196]  J. Griggs,et al.  American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[197]  Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[198]  Jay R. Harris,et al.  The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy , 1986, Cancer.

[199]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[200]  R. Livingston,et al.  Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[201]  R Coquard,et al.  Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[202]  C. Sweep,et al.  Final 10-year analysis of prospective multicenter Chemo N0 trial for validation of ASCO-recommended biomarkers uPA/PAI-1 for therapy decision making in node-negative breast cancer. , 2009, Journal of Clinical Oncology.

[203]  M. Buyse,et al.  Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[204]  Multi-agent chemotherapy for early breast cancer. , 2002, The Cochrane database of systematic reviews.

[205]  C. Loprinzi.  Follow-up care after breast cancer treatment. , 2004, Mayo Clinic women's healthsource.

[206]  W. Sauerbrei,et al.  Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[207]  R. Walker,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2005 .

[208]  Barbara L. Smith,et al.  Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[209]  Anthony Fyles,et al.  Long-term results of hypofractionated radiation therapy for breast cancer. , 2010, The New England journal of medicine.

[210]  D. Ghersi,et al.  Single agent versus combination chemotherapy for metastatic breast cancer. , 2009, The Cochrane database of systematic reviews.

[211]  J. Wunder,et al.  Acetabular Metastases: Planning for Reconstruction and Review of Results , 2003, Clinical orthopaedics and related research.

[212]  Renee F Wilson,et al.  Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer , 2008, Annals of Internal Medicine.

[213]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[214]  E. Harris.  Cardiac mortality and morbidity after breast cancer treatment. , 2008, Cancer control : journal of the Moffitt Cancer Center.

[215]  M. Morrow,et al.  Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[216]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[217]  P. Goodwin,et al.  Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009). , 2011, Journal of the National Cancer Institute.

[218]  T. Whelan,et al.  Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer , 2004, Canadian Medical Association Journal.

[219]  L. Gibson,et al.  Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. , 2007, The Cochrane database of systematic reviews.

[220]  J. Overgaard,et al.  Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[221]  J. Jacquemier,et al.  Local recurrence after breast‐conserving surgery and radiotherapy. Frequency, time course, and prognosis , 1989, Cancer.

[222]  M. Milella,et al.  Benefit of taxanes as adjuvant chemotherapy for early breast cancer , 2006, Cancer.

[223]  Zeljko Vujaskovic,et al.  Randomized trial of hyperthermia and radiation for superficial tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[224]  S. Tyldesley,et al.  Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[225]  Deborah Schrag,et al.  Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[226]  H. Rauschecker,et al.  Systemic therapy for treating locoregional recurrence in women with breast cancer. , 2001, The Cochrane database of systematic reviews.

[227]  M. Moran.  Impact of Pathological Characteristics on Local Relapse After Breast-Conserving Therapy: A Subgroup Analysis of the EORTC Boost Versus No Boost Trial , 2010 .

[228]  M. Amichetti,et al.  Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. , 2006, The Lancet. Oncology.

[229]  R Peto,et al.  Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials , 2011, The Lancet.

[230]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[231]  D. Clohisy.  Metastatic bone disease: future directions. , 2003, Clinical orthopaedics and related research.

[232]  A. Liberati,et al.  Follow-up strategies for women treated for early breast cancer. , 2005, The Cochrane database of systematic reviews.

[233]  Hans-Peter Sinn,et al.  International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[234]  V. Gebski,et al.  Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. , 2006, Journal of the National Cancer Institute.

[235]  T. Whelan,et al.  Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy , 2004, Canadian Medical Association Journal.

[236]  C. Lemanski,et al.  Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience. , 2002, International journal of radiation oncology, biology, physics.

[237]  G. Hortobagyi,et al.  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[238]  Nehmat Houssami,et al.  Review of Preoperative Magnetic Resonance Imaging (MRI) in Breast Cancer: Should MRI Be Performed on All Women with Newly Diagnosed, Early Stage Breast Cancer? , 2009, CA: a cancer journal for clinicians.

[239]  W. So,et al.  Effectiveness of exercise programmes on shoulder mobility and lymphoedema after axillary lymph node dissection for breast cancer: systematic review. , 2010, Journal of advanced nursing.

[240]  C. Sweep,et al.  Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. , 2001, Journal of the National Cancer Institute.

[241]  Paul K J Han,et al.  Communicating the Uncertainty of Harms and Benefits of Medical Interventions , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

[242]  D. Ghersi,et al.  Post-operative radiotherapy for ductal carcinoma in situ of the breast. , 2013, The Cochrane database of systematic reviews.

[243]  N. Weidner,et al.  Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[244]  I. Kunkler.  Adjuvant chest wall radiotherapy for breast cancer: black, white and shades of grey. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[245]  K L Resch,et al.  Exercise for women receiving adjuvant therapy for breast cancer. , 2006, The Cochrane database of systematic reviews.

[246]  M. Kaufmann,et al.  Hormonelle Folgetherapien nach Goserelin (Zoladex®) beim metastasierten Mammakarzinom prämenopausaler Patientinnen , 1991, Archives of Gynecology and Obstetrics.

[247]  D. Wickerham,et al.  Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[248]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[249]  T. Buchholz.  Radiation therapy for early-stage breast cancer after breast-conserving surgery. , 2009, The New England journal of medicine.

[250]  M. Venturini,et al.  Taxane-containing chemotherapy in the treatment of early breast cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[251]  R. Blamey,et al.  Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[252]  J. Bonneterre,et al.  Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[253]  D. Coyle,et al.  Surveillance mammography after treatment of primary breast cancer: a systematic review. , 2002, Breast.

[254]  P. Poortmans.  Evidence based radiation oncology: breast cancer. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[255]  N. Rowell.  Radiotherapy to the chest wall following mastectomy for node-negative breast cancer: a systematic review. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[256]  Thomas J. Smith,et al.  American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[257]  J. Boyages,et al.  Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. , 1999, Cancer.

[258]  S. Edge,et al.  Evidence and controversies in the use of post-mastectomy radiation. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[259]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[260]  Helmut Madjar,et al.  Role of Breast Ultrasound for the Detection and Differentiation of Breast Lesions , 2010, Breast Care.

[261]  T. Eberlein.  Lymphedema Therapy Reduces the Volume of Edema and Pain in Patients with Breast Cancer , 2008 .

[262]  T. Hope,et al.  Observing decision‐making in the general practice consultation: who makes which decisions? , 2006, Health expectations : an international journal of public participation in health care and health policy.

[263]  B. Ljung,et al.  HER2 testing in breast cancer: NCCN Task Force report and recommendations. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[264]  U. Chetty,et al.  Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. , 2006, Journal of the National Cancer Institute.

[265]  A. Taghian,et al.  Post-mastectomy radiation in large node-negative breast tumors: does size really matter? , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[266]  N. O’higgins,et al.  Principles and guidelines for surgeons--management of symptomatic breast cancer. On behalf of the European Society of Surgical Oncology. , 1998, Annales chirurgiae et gynaecologiae.

[267]  C. Grau,et al.  Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[268]  B. Hickey,et al.  Sequencing of chemotherapy and radiation therapy for early breast cancer. , 2006, The Cochrane database of systematic reviews.

[269]  Markus Hahn,et al.  Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review , 2009, BMC Cancer.

[270]  G. Bonadonna,et al.  Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. , 1995, JAMA.

[271]  K S Panageas,et al.  Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[272]  S. Schraub,et al.  Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[273]  G. Santamaría,et al.  Clinical axillary recurrence after sentinel node biopsy in breast cancer: a follow-up study of 220 patients , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[274]  Les Irwig,et al.  Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. , 2010, European journal of cancer.

[275]  A. Garg,et al.  Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy. , 2007, International journal of radiation oncology, biology, physics.

[276]  M. Reiss,et al.  Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[277]  Laurence Collette,et al.  Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial , 2007 .

[278]  G. Hortobagyi,et al.  Current management of advanced breast cancer. , 1996, Seminars in oncology.

[279]  B. Fisher,et al.  Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials , 2004, World Journal of Surgery.

[280]  Galina Velikova,et al.  Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[281]  L. Lostumbo,et al.  Prophylactic mastectomy for the prevention of breast cancer. , 2010, Cochrane Database of Systematic Reviews.

[282]  L. Jacobs,et al.  LYMPHEDEMA FOLLOWING BREAST CANCER TREATMENT, INCLUDING SENTINEL LYMPH NODE BIOPSY. , 2003 .